Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1-((((1r)-1-(3-((e)-2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)-cyclopropaneacetic Acid
2. Mk 0476
3. Mk-0476
4. Montelukast
5. Singulair
6. Sodium 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropylacetate
1. 151767-02-1
2. Singulair
3. Montair
4. Montelukast Sodium Salt
5. Montelukast Sodium [usan]
6. Montelukast (sodium)
7. Mk-476
8. Mk-0476
9. Montelukast Na
10. Montelukast (as Sodium)
11. Montelukast Monosodium Salt
12. U1o3j18sfl
13. Chebi:6993
14. Sodium (r,e)-2-(1-(((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)thio)methyl)cyclopropyl)acetate
15. 151767-02-1 (sodium)
16. Singular
17. Nsc-759107
18. Dsstox_cid_26450
19. Dsstox_rid_81624
20. Dsstox_gsid_46450
21. Cyclopropaneacetic Acid, 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)-, Sodium Salt, (r-(e))-
22. Kokast
23. Mls001304727
24. Sodium (r,e)-2-(1-((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propylthio)methyl)cyclopropyl)acetate
25. Cas-151767-02-1
26. Cyclopropaneacetic Acid, 1-[[[(1r)-1-[3-[(1e)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, Sodium Salt (1:1)
27. Smr000469188
28. Sodium;2-[1-[[(1r)-1-[3-[(e)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetate
29. Mk 476
30. Unii-u1o3j18sfl
31. Mk 0476
32. Kipres
33. Lukasm
34. Mfcd00931431
35. Singulair (tn)
36. Cpd000469188
37. Ncgc00164568-01
38. Montelukast Sodium- Bio-x
39. Schembl9414
40. Schembl9415
41. Mls001424198
42. Sodium 1-((((r)-m-((e)-2-(7-chloro-2-quinolyl)vinyl)-alpha-(o-(1-hydroxy-1-methylethyl)phenethyl)benzyl)thio)methyl)cyclopropaneacetate
43. Chembl1200681
44. Dtxsid8046450
45. Montelukast Sodium [jan]
46. Montelukast Sodium (jp17/usp)
47. Hms2051f18
48. Hms2235h19
49. Hms3885d11
50. Montelukast Sodium [vandf]
51. Montelukast Sodium [mart.]
52. Act06295
53. Montelukast Sodium [usp-rs]
54. Montelukast Sodium [who-dd]
55. Tox21_112197
56. Mk0476
57. S4211
58. Akos015833416
59. Akos032949734
60. Tox21_112197_1
61. Am62787
62. Bcp9000959
63. Ccg-101049
64. Cs-0548
65. Ks-1087
66. Nc00299
67. Nsc 759107
68. Montelukast Monosodium Salt [mi]
69. Montelukast Sodium [orange Book]
70. Montelukast Sodium [ep Monograph]
71. Ncgc00164568-04
72. Bm164606
73. Cyclopropaneacetic Acid, 1-((((1r)-1-(3-((1e)-2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)-, Monosodium Salt
74. Hy-13315
75. Montelukast Sodium [usp Monograph]
76. M2340
77. Sw197679-2
78. 2-[1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]thio]methyl]cyclopropyl]acetate; Sodium
79. D00529
80. J-008841
81. J-522711
82. L-706631
83. Q27107384
84. 1-((((1r)-1-(3-((1e)-2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic Acid Monosodium Salt
85. 1-[[[(1r)-1-[3-[(1e)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic Acid Sodium Salt
86. 1-[[[(r)-1-[3-[2-(7-chloro-2-quinolyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-1-cyclopropaneacetic Acid Sodium Salt
87. Cyclopropaneacetic Acid,1-[[[(1r)-1-[3-[(1e)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-,sodium Salt
88. Sodium {1-[({(1r)-1-{3-[(e)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetate
89. Sodium 1-((((r)-m -((e)-2-(7-chloro-2-quinolyl)vinyl)-alpha-(o-(1-hydroxy-1-methylethyl)phenethyl)benzyl)thio)methyl)cyclopropaneacetate
90. Sodium 1-((((r)-m-((e)-2-(7-chloro-2-quinolyl)vinyl)-.alpha.-(o-(1-hydroxy-1-methylethyl)phenethyl)benzyl)thio)methyl)cyclopropaneacetate
91. Sodium 1-[[[(1r)-1-[3-[(1e)-2-(7-chloroquinoline-2-yl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetate
92. Sodium 2-(1-((((r)-1-(3-((e)-2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)sulfanyl)methyl)cyclopropyl)acetate
93. Sodium(r,e)-2-(1-(((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)thio)methyl)cyclopropyl)acetate
| Molecular Weight | 608.2 g/mol |
|---|---|
| Molecular Formula | C35H35ClNNaO3S |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 12 |
| Exact Mass | 607.1923871 g/mol |
| Monoisotopic Mass | 607.1923871 g/mol |
| Topological Polar Surface Area | 98.6 Ų |
| Heavy Atom Count | 42 |
| Formal Charge | 0 |
| Complexity | 898 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 4 | |
|---|---|
| Drug Name | Montelukast sodium |
| PubMed Health | Montelukast (By mouth) |
| Drug Classes | Anti-Inflammatory |
| Drug Label | Montelukast sodium, the active ingredient in montelukast sodium tablets and montelukast sodium chewable tablets, is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLT1 receptor.Montelukast sodi... |
| Active Ingredient | Montelukast sodium |
| Dosage Form | Tablet; Granule; Tablet, chewable |
| Route | Oral |
| Strength | eq 4mg base; eq 5mg base; eq 4mg base/packet; eq 10mg base |
| Market Status | Prescription |
| Company | Vintage Pharms; Mylan Pharms; Hetero Labs Ltd V; Apotex; Accord Hlthcare; Aurobindo Pharma; Torrent Pharms; Sandoz; Roxane; Glenmark Generics; Teva Pharms; Macleods Pharms; Kudco Ireland; Dr Reddys Labs |
| 2 of 4 | |
|---|---|
| Drug Name | Singulair |
| Drug Label | Montelukast sodium, the active ingredient in SINGULAIRRegistered trademark of MERCK & CO., Inc.COPYRIGHT 1998-2009 MERCK & CO., Inc.All rights reserved, is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl |
| Active Ingredient | Montelukast sodium |
| Dosage Form | Tablet; Granule; Tablet, chewable |
| Route | Oral |
| Strength | eq 4mg base; eq 5mg base; eq 4mg base/packet; eq 10mg base |
| Market Status | Prescription |
| Company | Merck |
| 3 of 4 | |
|---|---|
| Drug Name | Montelukast sodium |
| PubMed Health | Montelukast (By mouth) |
| Drug Classes | Anti-Inflammatory |
| Drug Label | Montelukast sodium, the active ingredient in montelukast sodium tablets and montelukast sodium chewable tablets, is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLT1 receptor.Montelukast sodi... |
| Active Ingredient | Montelukast sodium |
| Dosage Form | Tablet; Granule; Tablet, chewable |
| Route | Oral |
| Strength | eq 4mg base; eq 5mg base; eq 4mg base/packet; eq 10mg base |
| Market Status | Prescription |
| Company | Vintage Pharms; Mylan Pharms; Hetero Labs Ltd V; Apotex; Accord Hlthcare; Aurobindo Pharma; Torrent Pharms; Sandoz; Roxane; Glenmark Generics; Teva Pharms; Macleods Pharms; Kudco Ireland; Dr Reddys Labs |
| 4 of 4 | |
|---|---|
| Drug Name | Singulair |
| Drug Label | Montelukast sodium, the active ingredient in SINGULAIRRegistered trademark of MERCK & CO., Inc.COPYRIGHT 1998-2009 MERCK & CO., Inc.All rights reserved, is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl |
| Active Ingredient | Montelukast sodium |
| Dosage Form | Tablet; Granule; Tablet, chewable |
| Route | Oral |
| Strength | eq 4mg base; eq 5mg base; eq 4mg base/packet; eq 10mg base |
| Market Status | Prescription |
| Company | Merck |
Asthma
Anti-Asthmatic Agents
Drugs that are used to treat asthma. (See all compounds classified as Anti-Asthmatic Agents.)
Cytochrome P-450 CYP1A2 Inducers
Drugs and compounds that induce the synthesis of CYTOCHROME P-450 CYP1A2. (See all compounds classified as Cytochrome P-450 CYP1A2 Inducers.)
Leukotriene Antagonists
A class of drugs designed to prevent leukotriene synthesis or activity by blocking binding at the receptor level. (See all compounds classified as Leukotriene Antagonists.)
API SUPPLIERS
Together we can improve the quality of life
Zeon Pharma is a manufacturer and supplier of APIs & Intermediates.
Jai Radhe Sales is your partner for all your sourcing needs.
Minakem is manufacturing small molecules APIs including corticosteroids
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16243
Submission : 2002-11-15
Status : Active
Type : II
Inke S.A: APIs manufacturing plant.
Registration Number : 227MF10180
Registrant's Address : Area Industrial del Llobregat, C/Argent 1,08755 Castellbisbal Barcelona SPAIN
Initial Date of Registration : 2015-07-13
Latest Date of Registration :
| Available Reg Filing : ASMF |
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Registrant Name : Toru Co., Ltd.
Registration Date : 2021-05-04
Registration Number : 20210504-209-J-753
Manufacturer Name : Metrochem API Private Limited (Unit-I)
Manufacturer Address : Plot No. 62/C/6, Pipeline Road, Phase - I, IDA., Jeedimetla, Quthbullapur Mandal Medchal District - 500 055 Telangana, India
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-02-18
Pay. Date : 2012-12-31
DMF Number : 24516
Submission : 2010-12-31
Status : Active
Type : II
Certificate Number : R1-CEP 2012-115 - Rev 03
Issue Date : 2023-07-12
Type : Chemical
Substance Number : 2583
Status : Valid
Registration Number : 307MF10039
Registrant's Address : 8-2-337, Road No. 3,Banjara Hills,Hyderabad 500 034,TELANGANA,INDIA
Initial Date of Registration : 2025-02-26
Latest Date of Registration :
Date of Issue : 2025-07-25
Valid Till : 2028-06-04
Written Confirmation Number : WC-0043
Address of the Firm :
NDC Package Code : 55111-084
Start Marketing Date : 2010-12-31
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Pamirae Co., Ltd.
Registration Date : 2022-06-29
Registration Number : 20220629-209-J-1272
Manufacturer Name : Dr. Reddy's Laboratories Ltd.
Manufacturer Address : Chemical Technical Operations-Unit-Ⅴ, Peddadevulapally Village, Tripuraram Mandal, Nalgonda District, 508 207, Telangana State, India
Aarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.
HRV Pharma - Market Expansion Leader in Pharmaceuticals.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
Minakem is manufacturing small molecules APIs including corticosteroids
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16243
Submission : 2002-11-15
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Complete
Rev. Date : 2015-02-18
Pay. Date : 2012-12-31
DMF Number : 24516
Submission : 2010-12-31
Status : Active
Type : II
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19829
Submission : 2006-10-04
Status : Active
Type : II
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : Complete
Rev. Date : 2017-10-20
Pay. Date : 2017-02-22
DMF Number : 31413
Submission : 2017-05-09
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 24324
Submission : 2010-11-02
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-07-22
Pay. Date : 2012-12-03
DMF Number : 21702
Submission : 2008-06-16
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2015-05-04
Pay. Date : 2015-04-29
DMF Number : 20580
Submission : 2007-06-07
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-07-11
Pay. Date : 2013-06-26
DMF Number : 20425
Submission : 2007-03-26
Status : Active
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] JDMF
Inke S.A: APIs manufacturing plant.
Registration Number : 227MF10180
Registrant's Address : Area Industrial del Llobregat, C/Argent 1,08755 Castellbisbal Barcelona SPAIN
Initial Date of Registration : 2015-07-13
Latest Date of Registration : 2016-11-22
Inke S.A: APIs manufacturing plant.
Registration Number : 228MF10055
Registrant's Address : Area Industrial del Llobregat, C/Argent 1,08755 Castellbisbal Barcelona SPAIN
Initial Date of Registration : 2016-02-18
Latest Date of Registration : 2016-11-22
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Registration Number : 307MF10039
Registrant's Address : 8-2-337, Road No. 3,Banjara Hills,Hyderabad 500 034,TELANGANA,INDIA
Initial Date of Registration : 2025-02-26
Latest Date of Registration : 2025-02-26
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
Registration Number : 227MF10050
Registrant's Address : Plot No. 2G, 2H, 2I, Udyog Vihar, Greater Noida - 201 308 (U.P.) India
Initial Date of Registration : 2015-02-18
Latest Date of Registration : 2022-10-19
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
Registration Number : 305MF10076
Registrant's Address : Plot No. 2G, 2H, 2I, Udyog Vihar, Greater Noida - 201 308 (U.P.) India
Initial Date of Registration : 2023-07-05
Latest Date of Registration : 2023-07-05
Registration Number : 306MF10009
Registrant's Address : 174, Sirok-ro, Asan-si, Chungcheongnam-do, KOREA
Initial Date of Registration : 2024-01-17
Latest Date of Registration : 2024-01-17
Registration Number : 303MF10148
Registrant's Address : No. 1, North Outer Ring Road, Feixian County, Shandong Province, China
Initial Date of Registration : 2021-09-17
Latest Date of Registration : 2021-09-17
Registration Number : 306MF10123
Registrant's Address : 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar, Sector-20, Gurugram-Haryana, 1...
Initial Date of Registration : 2024-09-11
Latest Date of Registration : 2024-09-11
Registration Number : 227MF10022
Registrant's Address : Plot No. 564/A/22, Road No. 92, Jubilee Hills, Hyderabad-500096, Telangana, India
Initial Date of Registration : 2015-01-23
Latest Date of Registration : 2021-02-24
Registration Number : 229MF10094
Registrant's Address : Jiangkou Development Zone, Huangyan, Taizhou City, Zhejiang Province, People's Republ...
Initial Date of Registration : 2017-05-16
Latest Date of Registration : 2025-07-23
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
Isatuximab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Multiple Myeloma.
Lead Product(s): Isatuximab,Montelukast Sodium,Dexamethasone,Paracetamol,Diphenhydramine,Methylprednisolone,Carfilzomib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 10, 2024
Lead Product(s) : Isatuximab,Montelukast Sodium,Dexamethasone,Paracetamol,Diphenhydramine,Methylprednisolone,Carfilzomib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Isatuximab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Multiple Myeloma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 10, 2024
Details:
Agalsidase Beta is a Enzyme drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Fabry Disease.
Lead Product(s): Agalsidase Beta,Paracetamol,Diphenhydramine,Dexamethasone,Montelukast Sodium,Loratadine,Cetirizine,Fexofenadine Hydrochloride
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Enzyme
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 31, 2023
Lead Product(s) : Agalsidase Beta,Paracetamol,Diphenhydramine,Dexamethasone,Montelukast Sodium,Loratadine,Cetirizine,Fexofenadine Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme
Details : Agalsidase Beta is a Enzyme drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Fabry Disease.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
August 31, 2023
Details:
Isatuximab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Multiple Myeloma.
Lead Product(s): Isatuximab,Carfilzomib,Dexamethasone,Montelukast Sodium,Paracetamol,Diphenhydramine,Methylprednisolone
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 30, 2023
Lead Product(s) : Isatuximab,Carfilzomib,Dexamethasone,Montelukast Sodium,Paracetamol,Diphenhydramine,Methylprednisolone
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Isatuximab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Multiple Myeloma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
January 30, 2023
Details:
Isatuximab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Multiple Myeloma.
Lead Product(s): Isatuximab,Dexamethasone,Pomalidomide,Montelukast Sodium,Paracetamol,Diphenhydramine,Methylprednisolone
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 06, 2022
Lead Product(s) : Isatuximab,Dexamethasone,Pomalidomide,Montelukast Sodium,Paracetamol,Diphenhydramine,Methylprednisolone
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
Details : Isatuximab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Multiple Myeloma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 06, 2022
Details:
Isatuximab is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Immune System Diseases.
Lead Product(s): Isatuximab,Paracetamol,Ranitidine,Diphenhydramine,Methylprednisolone,Montelukast Sodium
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 04, 2020
Lead Product(s) : Isatuximab,Paracetamol,Ranitidine,Diphenhydramine,Methylprednisolone,Montelukast Sodium
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Isatuximab is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Immune System Diseases.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 04, 2020
Details:
Isatuximab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Multiple Myeloma.
Lead Product(s): Isatuximab,Lenalidomide,Dexamethasone,Montelukast Sodium,Paracetamol,Diphenhydramine,Methylprednisolone
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 17, 2020
Lead Product(s) : Isatuximab,Lenalidomide,Dexamethasone,Montelukast Sodium,Paracetamol,Diphenhydramine,Methylprednisolone
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Isatuximab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Multiple Myeloma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
February 17, 2020
Details:
Montelukast Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Montelukast Sodium,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 24, 2012
Lead Product(s) : Montelukast Sodium,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Montelukast Sodium Oral Granules 4mg Under Fasting Condition
Details : Montelukast Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 24, 2012
Details:
Montelukast Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Montelukast Sodium,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 24, 2012
Lead Product(s) : Montelukast Sodium,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Montelukast Sodium Oral Granules 4mg Under Fed Condition
Details : Montelukast Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 24, 2012
Details:
Montelukast Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Montelukast Sodium,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 29, 2012
Lead Product(s) : Montelukast Sodium,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Montelukast Sodium Chewable Tablets 4mg and 5mg Under Fasting Condition
Details : Montelukast Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 29, 2012
Details:
Montelukast Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Montelukast Sodium,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 29, 2012
Lead Product(s) : Montelukast Sodium,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Montelukast Sodium Chewable Tablets 4mg and 5mg Under Fed Condition
Details : Montelukast Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 29, 2012
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
Zeon Pharma is a manufacturer and supplier of APIs & Intermediates.
2-(2-[3(S)-[2-(7-Chloro 2quiolinyl ethnyl)Phenyl}3...
CAS Number : 287930-77-2
End Use API : Montelukast Sodium
About The Company : Zeon Pharma Industries India Pvt ltd is an ISO & GMP certified manufacturer of Bulk drugs & Intermediate and also supplies our associate manufacturing plant API...
Aarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.
2-[2-[3(S)-3[2-(7-chloro-2-quinolinyl) ethenyl] ph...
CAS Number : 142569-70-8
End Use API : Montelukast Sodium
About The Company : Aarti Pharmalab, earlier the pharma division of Aarti Industries, is a leading Indian manufacturer of APIs. It has dedicated facilities to manufacture HPAPIs, c...
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
2-[1-(Mercaptomethyl)cyclopropyl]acetic acid
CAS Number : 162515-68-6
End Use API : Montelukast Sodium
About The Company : Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediate...
CAS Number : 4965-33-7
End Use API : Montelukast Sodium
About The Company : Anvitha Life Care Private Limited, founded in 2016 by Dr. T. Prakasam and a team of experienced scientists and technocrats with over 80 years of combined expert...
4-Methoxy benzene sulfonyl chloride
CAS Number : 98-68-0
End Use API : Montelukast Sodium
About The Company : Our journey began in 1969, with our first manufacturing facility Jet Chemicals Pvt. Ltd (JCPL), a pioneer in manufacturing Pharmaceutical Excipients (Saccharin ...
1-(Mercaptomethyl)cyclopropane acetic acid
CAS Number : 162515-68-6
End Use API : Montelukast Sodium
About The Company : Ceyone Life Sciences specializes in providing research-oriented chemistry services and manufacturing niche chemicals, intermediates, and APIs. The company is fo...
(S)-1-(3-(2-(7-Chloroquinolin-2-yl)vinyl) phenyl)-...
CAS Number : 142569-70-8
End Use API : Montelukast Sodium
About The Company : Ceyone Life Sciences specializes in providing research-oriented chemistry services and manufacturing niche chemicals, intermediates, and APIs. The company is fo...
2-(2-[3(S)-[2-(7-Chloro 2Quiolinyl Ethnyl)Phenyl}3...
CAS Number :
End Use API : Montelukast Sodium
About The Company : Hoventa Pharma is in the business of manufacturing APIs for over three decades.We offer various kinds of services in addition to supplies of APIs, we undertake ...
Methyl2-(3-(3-(2-(7-Chloro 2 Quinolinyl) Ethenyl )...
CAS Number :
End Use API : Montelukast Sodium
About The Company : Hoventa Pharma is in the business of manufacturing APIs for over three decades.We offer various kinds of services in addition to supplies of APIs, we undertake ...
1-(Thiomethyl)-Cyclopropane Acetic Acid
CAS Number :
End Use API : Montelukast Sodium
About The Company : Hoventa Pharma is in the business of manufacturing APIs for over three decades.We offer various kinds of services in addition to supplies of APIs, we undertake ...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
Zeon Pharma is a manufacturer and supplier of APIs & Intermediates.
Regulatory Info :
Registration Country : India
Brand Name : Montelukast Sodium
Dosage Form : DC Granules
Dosage Strength :
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : Montelukast Zentiva film-coated tablets
Dosage Form : Film Coated Tablet
Dosage Strength : 10mg
Packaging :
Approval Date : 27/03/2013
Application Number : 62666
Regulatory Info : Allowed
Registration Country : Switzerland
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info : Withdrawn
Registration Country : Malta
Brand Name : Montelukast Zentiva Chewable
Dosage Form : Chewable Tablet
Dosage Strength : 5MG
Packaging :
Approval Date : 2015-05-20
Application Number :
Regulatory Info : Withdrawn
Registration Country : Malta
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info : Withdrawn
Registration Country : Malta
Brand Name : Montelukast Zentiva
Dosage Form : Film Coated Tablet
Dosage Strength : 10MG
Packaging :
Approval Date : 2015-06-15
Application Number :
Regulatory Info : Withdrawn
Registration Country : Malta
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : Generic
Registration Country : South Africa
Brand Name : Topraz 4
Dosage Form : CHU
Dosage Strength : 4mg
Packaging : 30X1mg
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : Generic
Registration Country : South Africa
Brand Name : Topraz 4
Dosage Form : CHU
Dosage Strength : 4mg
Packaging : 28X1mg
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : Generic
Registration Country : South Africa
Brand Name : Topraz 5
Dosage Form : CHU
Dosage Strength : 5mg
Packaging : 30X1mg
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : Generic
Registration Country : South Africa
Brand Name : Topraz 5
Dosage Form : CHU
Dosage Strength : 5mg
Packaging : 28X1mg
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : Generic
Registration Country : South Africa
Brand Name : Topraz 10
Dosage Form : FCT
Dosage Strength : 10mg
Packaging : 30X1mg
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : Generic
Registration Country : South Africa
Brand Name : Topraz 10
Dosage Form : FCT
Dosage Strength : 10mg
Packaging : 28X1mg
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]South Africa
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Dossiers
Zeon Pharma is a manufacturer and supplier of APIs & Intermediates.
Regulatory Info :
Registration Country : India
Brand Name : Montelukast Sodium
Dosage Form : DC Granules
Dosage Strength :
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Zeon Pharma is a manufacturer and supplier of APIs & Intermediates.
Packaging :
Regulatory Info :
Dosage : DC Granules
Dosage Strength :
Brand Name : Montelukast Sodium
Approval Date :
Application Number :
Registration Country : India
Emay Pharmaceuticals is a GMP-certified API manufacturing company.
Regulatory Info :
Registration Country : India
Brand Name : Montelukast
Dosage Form : Granules
Dosage Strength : 7%
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Emay Pharmaceuticals is a GMP-certified API manufacturing company.
Packaging :
Regulatory Info :
Dosage : Granules
Dosage Strength : 7%
Brand Name : Montelukast
Approval Date :
Application Number :
Registration Country : India
We are the TIEFENBACHER GROUP, Health Pioneers since 1963.
Regulatory Info : Registered in EU
Registration Country : Germany
Brand Name :
Dosage Form : Chewable Tablet
Dosage Strength : 4MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Registered in EU
Registration Country : Germany
We are the TIEFENBACHER GROUP, Health Pioneers since 1963.
Packaging :
Regulatory Info : Registered in EU
Dosage : Chewable Tablet
Dosage Strength : 4MG
Brand Name :
Approval Date :
Application Number :
Registration Country : Germany
We are the TIEFENBACHER GROUP, Health Pioneers since 1963.
Regulatory Info : Registered in EU
Registration Country : Germany
Brand Name :
Dosage Form : Chewable Tablet
Dosage Strength : 5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Registered in EU
Registration Country : Germany
We are the TIEFENBACHER GROUP, Health Pioneers since 1963.
Packaging :
Regulatory Info : Registered in EU
Dosage : Chewable Tablet
Dosage Strength : 5MG
Brand Name :
Approval Date :
Application Number :
Registration Country : Germany
We are the TIEFENBACHER GROUP, Health Pioneers since 1963.
Regulatory Info : Registered in EU
Registration Country : Germany
Brand Name :
Dosage Form : Film Coated Tablet
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Registered in EU
Registration Country : Germany
We are the TIEFENBACHER GROUP, Health Pioneers since 1963.
Packaging :
Regulatory Info : Registered in EU
Dosage : Film Coated Tablet
Dosage Strength : 10MG
Brand Name :
Approval Date :
Application Number :
Registration Country : Germany
Octavius Pharma has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
Regulatory Info :
Registration Country : India
Brand Name : Montelukast Sodium
Dosage Form : Chewable Tablet
Dosage Strength : 4MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Octavius Pharma has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
Packaging :
Regulatory Info :
Dosage : Chewable Tablet
Dosage Strength : 4MG
Brand Name : Montelukast Sodium
Approval Date :
Application Number :
Registration Country : India
Octavius Pharma has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
Regulatory Info :
Registration Country : India
Brand Name : Montelukast Sodium
Dosage Form : Chewable Tablet
Dosage Strength : 5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Octavius Pharma has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
Packaging :
Regulatory Info :
Dosage : Chewable Tablet
Dosage Strength : 5MG
Brand Name : Montelukast Sodium
Approval Date :
Application Number :
Registration Country : India
Octavius Pharma has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
Regulatory Info :
Registration Country : India
Brand Name : Montelukast Sodium
Dosage Form : Tablet
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Octavius Pharma has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
Packaging :
Regulatory Info :
Dosage : Tablet
Dosage Strength : 10MG
Brand Name : Montelukast Sodium
Approval Date :
Application Number :
Registration Country : India
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Regulatory Info : EU Approved
Registration Country : Greece
Brand Name :
Dosage Form : Film Coated Tablet
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : EU Approved
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Packaging :
Regulatory Info : EU Approved
Dosage : Film Coated Tablet
Dosage Strength : 10MG
Brand Name :
Approval Date :
Application Number :
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Regulatory Info : EU Approved
Registration Country : Greece
Brand Name :
Dosage Form : Chewable Tablet
Dosage Strength : 4MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : EU Approved
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Packaging :
Regulatory Info : EU Approved
Dosage : Chewable Tablet
Dosage Strength : 4MG
Brand Name :
Approval Date :
Application Number :
Registration Country : Greece
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - TABLET;ORAL - EQ 10MG BASE
USFDA APPLICATION NUMBER - 20829
DOSAGE - TABLET, CHEWABLE;ORAL - EQ 4MG BASE
USFDA APPLICATION NUMBER - 20830
DOSAGE - TABLET, CHEWABLE;ORAL - EQ 5MG BASE
USFDA APPLICATION NUMBER - 20830
DOSAGE - GRANULE;ORAL - EQ 4MG BASE/PACKET
USFDA APPLICATION NUMBER - 21409
Related Excipient Companies
Minakem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharm-RX Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Boai NKY Pharmaceuticals Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Minbiotech
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kirsch Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Aeon Procare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Alcedo Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ashland
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Bioplus Life Sciences
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Clariant
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Esteem Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Huzhou Sunflower Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Keval Exports
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nitika Pharmaceutical Specialities
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nomisma Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qianhao Chemical (Hebei) Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shijiazhuang Huaxu Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Silverline Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Coating Systems & Additives
Direct Compression
Disintegrants & Superdisintegrants
Granulation
Thickeners and Stabilizers
Taste Masking
Controlled & Modified Release
Lubricants & Glidants
Chewable & Orodispersible Aids
Topical
Solubilizers
Film Formers & Plasticizers
Co-Processed Excipients
Parenteral
Rheology Modifiers
Empty Capsules
API Stability Enhancers
Coloring Agents
Emulsifying Agents
Vegetarian Capsules
Surfactant & Foaming Agents
Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Regulatory FDF Prices
Synergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.
RX/OTC/DISCN : DISCN
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 10MG BASE
Price Per Pack :
Published in :
Country : USA
RX/OTC/DISCN : DISCN
Towa Pharma is dedicated to researching, developing, producing, and promoting generic drugs.
RX/OTC/DISCN :
Dosage Form : Coated Tablets
Dosage Strength : 10 mg
Price Per Pack (Euro) : 14.5
Published in :
Country : Italy
RX/OTC/DISCN :
Towa Pharma is dedicated to researching, developing, producing, and promoting generic drugs.
RX/OTC/DISCN :
Dosage Form : Chewable Tablets
Dosage Strength : 4 mg
Price Per Pack (Euro) : 14.5
Published in :
Country : Italy
RX/OTC/DISCN :
Towa Pharma is dedicated to researching, developing, producing, and promoting generic drugs.
RX/OTC/DISCN :
Dosage Form : Chewable Tablets
Dosage Strength : 5 mg
Price Per Pack (Euro) : 14.5
Published in :
Country : Italy
RX/OTC/DISCN :
RX/OTC/DISCN :
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 10 mg
Price Per Pack (Euro) : 19.173
Published in :
Country : Norway
RX/OTC/DISCN :
RX/OTC/DISCN :
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 10 mg
Price Per Pack (Euro) : 58.454
Published in :
Country : Norway
RX/OTC/DISCN :
RX/OTC/DISCN :
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 10 mg
Price Per Pack (Euro) : 19.173
Published in :
Country : Norway
RX/OTC/DISCN :
RX/OTC/DISCN :
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 10 mg
Price Per Pack (Euro) : 57.376
Published in :
Country : Norway
RX/OTC/DISCN :
RX/OTC/DISCN :
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 10 mg
Price Per Pack (Euro) : 19.173
Published in :
Country : Norway
RX/OTC/DISCN :
RX/OTC/DISCN :
Farm Agon
Dosage Form : Antic-calc Tablet
Dosage Strength : 10 mg
Price Per Pack (Euro) : 19.173
Published in :
Country : Norway
RX/OTC/DISCN :
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
APIs
Reply
01 Feb 2025
Reply
13 Jan 2025
Reply
08 Jul 2024
Reply
22 Nov 2023
Reply
01 Jun 2023
Reply
26 May 2023
Reply
13 May 2023
Reply
04 Apr 2023
Reply
23 Mar 2023
Reply
11 Feb 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
EDQM
CAS Number : 577953-88-9
Quantity Per Vial : 0.1 mg
Sale Unit : 1
Order Code : Y0001433
Batch No : 3
Price (€) : 79
Storage : +5°C ± 3°C
CAS Number : n/a
Quantity Per Vial : 150 mg
Sale Unit : 1
Order Code : Y0001436
Batch No : 2
Price (€) : 79
Storage : +5°C ± 3°C
Montelukast for peak identification
CAS Number : 151767-02-1
Quantity Per Vial : 20 mg
Sale Unit : 1
Order Code : Y0001435
Batch No : 3
Price (€) : 79
Storage : +5°C ± 3°C
CAS Number : 151767-02-1
Quantity Per Vial : 20 mg
Sale Unit : 1
Order Code : Y0001434
Batch No : 2
Price (€) : 79
Storage : +5°C ± 3°C
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]USP
Others
Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.
CAS Number : 151767-02-1
Quantity Per Vial :
Sale Unit :
Price : $164.00
Details :
Monograph : PHR1603-1G
Storage : +2°C to +8°C
Code/Batch No :
CAS Number : 142147-98-6
Quantity Per Vial :
Sale Unit :
Price :
Details : In stock
Monograph :
Storage :
Code/Batch No : M0005.16
Montelukast EP Impurity D(R,R-Isomer)
CAS Number : 1187586-61-3
Quantity Per Vial :
Sale Unit :
Price :
Details : In stock
Monograph :
Storage :
Code/Batch No : M0005.18
Montelukast EP Impurity E(R,S-Isomer)
CAS Number : 1187586-58-8
Quantity Per Vial :
Sale Unit :
Price :
Details : In stock
Monograph :
Storage :
Code/Batch No : M0005.36
Montelukast EP Impurity G (cis-Montelukast)
CAS Number : 774538-96-4
Quantity Per Vial :
Sale Unit :
Price :
Details : In stock
Monograph :
Storage :
Code/Batch No : M0005.10
CAS Number : 158966-92-8
Quantity Per Vial :
Sale Unit :
Price :
Details : In stock
Monograph :
Storage :
Code/Batch No : M0005.33
CAS Number : 918972-54-0
Quantity Per Vial :
Sale Unit :
Price :
Details : In stock
Monograph :
Storage :
Code/Batch No : M0005.08
Montelukast Sulfoxide Impurity A
CAS Number : 1152185-58-4
Quantity Per Vial :
Sale Unit :
Price :
Details : In stock
Monograph :
Storage :
Code/Batch No : M0005.05
Montelukast for Peak Identification (20 mg)
CAS Number :
Quantity Per Vial : 20
Sale Unit : mg
Price : $853.00
Details : Material Origin- Chemical Synthesis; USMCA- N...
Monograph :
Storage :
Code/Batch No : Catalog #1446837 / R04260
CAS Number :
Quantity Per Vial : 20
Sale Unit : mg
Price : $853.00
Details : Material Origin- Chemical Synthesis; USMCA- N...
Monograph :
Storage :
Code/Batch No : Catalog #1446848 / R031T0
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ANALYTICAL
ABOUT THIS PAGE
88
PharmaCompass offers a list of Montelukast Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Montelukast Sodium manufacturer or Montelukast Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Montelukast Sodium manufacturer or Montelukast Sodium supplier.
PharmaCompass also assists you with knowing the Montelukast Sodium API Price utilized in the formulation of products. Montelukast Sodium API Price is not always fixed or binding as the Montelukast Sodium Price is obtained through a variety of data sources. The Montelukast Sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Montelukast manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Montelukast, including repackagers and relabelers. The FDA regulates Montelukast manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Montelukast API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Montelukast manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Montelukast supplier is an individual or a company that provides Montelukast active pharmaceutical ingredient (API) or Montelukast finished formulations upon request. The Montelukast suppliers may include Montelukast API manufacturers, exporters, distributors and traders.
click here to find a list of Montelukast suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Montelukast DMF (Drug Master File) is a document detailing the whole manufacturing process of Montelukast active pharmaceutical ingredient (API) in detail. Different forms of Montelukast DMFs exist exist since differing nations have different regulations, such as Montelukast USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Montelukast DMF submitted to regulatory agencies in the US is known as a USDMF. Montelukast USDMF includes data on Montelukast's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Montelukast USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Montelukast suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Montelukast Drug Master File in Japan (Montelukast JDMF) empowers Montelukast API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Montelukast JDMF during the approval evaluation for pharmaceutical products. At the time of Montelukast JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Montelukast suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Montelukast Drug Master File in Korea (Montelukast KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Montelukast. The MFDS reviews the Montelukast KDMF as part of the drug registration process and uses the information provided in the Montelukast KDMF to evaluate the safety and efficacy of the drug.
After submitting a Montelukast KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Montelukast API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Montelukast suppliers with KDMF on PharmaCompass.
A Montelukast CEP of the European Pharmacopoeia monograph is often referred to as a Montelukast Certificate of Suitability (COS). The purpose of a Montelukast CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Montelukast EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Montelukast to their clients by showing that a Montelukast CEP has been issued for it. The manufacturer submits a Montelukast CEP (COS) as part of the market authorization procedure, and it takes on the role of a Montelukast CEP holder for the record. Additionally, the data presented in the Montelukast CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Montelukast DMF.
A Montelukast CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Montelukast CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Montelukast suppliers with CEP (COS) on PharmaCompass.
A Montelukast written confirmation (Montelukast WC) is an official document issued by a regulatory agency to a Montelukast manufacturer, verifying that the manufacturing facility of a Montelukast active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Montelukast APIs or Montelukast finished pharmaceutical products to another nation, regulatory agencies frequently require a Montelukast WC (written confirmation) as part of the regulatory process.
click here to find a list of Montelukast suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Montelukast as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Montelukast API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Montelukast as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Montelukast and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Montelukast NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Montelukast suppliers with NDC on PharmaCompass.
Montelukast Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Montelukast GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Montelukast GMP manufacturer or Montelukast GMP API supplier for your needs.
A Montelukast CoA (Certificate of Analysis) is a formal document that attests to Montelukast's compliance with Montelukast specifications and serves as a tool for batch-level quality control.
Montelukast CoA mostly includes findings from lab analyses of a specific batch. For each Montelukast CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Montelukast may be tested according to a variety of international standards, such as European Pharmacopoeia (Montelukast EP), Montelukast JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Montelukast USP).
Comment (4)
